MD Jan Andrzej Walewski, Ph.D.

Publikovaná abstrakta

• A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma
• A RETROSPECTIVE STUDY TO ASSESS RELATIVE DOSE INTENSITIES IN PATIENTS WITH LYMPHOMA IN CENTRAL EUROPEAN COUNTRIES
• BORTEZOMIB-RITUXIMAB RESULTS IN IMPROVED PFS AND RESPONSE RATES VERSUS RITUXIMAB, AND QUALITY OF RESPONSE IS ASSOCIATED WITH IMPROVED OUTCOMES, IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL)
• Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort
• EFFICIENT HDAC INHIBITION AND TARC REDUCTION IN PATIENTS WITH REFRACTORY HODGKIN LYMPHOMA TREATED WITH RESMINOSTAT - PK/PD DATA FROM THE PHASE II SAPHIRE STUDY
• European MCL Network: An Update on Current First Line Trials.
• Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma
• First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
• First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant
• Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chem...
• IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR’S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
• INCIDENCE, CHARACTERISTICS AND OUTCOME OF CNS INVOLVEMENT IN MANTLE CELL LYMPHOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS FROM THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK
• Outcome and Prognostic Factors in Patients with Mantle Cell Lymphoma Relapsing After Autologous Stem Cell Transplantation: A Retrospective Study of the EBMT
• Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
• Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study
• QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR’S CHOICE: MCL-002 (SPRINT) TRIAL
• R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma
• Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (
• RITUXIMAB MAINTENANCE SIGNIFICANTLY PROLONGS DURATION OF REMISSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. FIRST RESULTS OF A RANDOMIZED TRIAL OF THE EUROPEAN MCL NETWORK
• Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant
• Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.
• The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International